Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* WHITESIDES GEORGE M						2. Issuer Name and Ticker or Trading Symbol Theravance Biopharma, Inc. [TBPH]							of Reportin cable) or	g Pers	on(s) to Issu 10% Ow	
(Last) (First) (Middle) C/O THERAVANCE BIOPHARMA US, INC. 901 GATEWAY BOULEVARD					3. Date of Earliest Transaction (Month/Day/Year) 06/03/2014							Officer below)	(give title		Other (s below)	pecify
(Street) SOUTH SAN FRANCISCO CA		94080		4. If Amendment, Date of Original Filed (Month/Day/Year)							e) <mark>X</mark> Form fi Form fi	Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State) (Zip)																
		Tab	le I - Non-E	Deriva	tive S	ecuritie	s Ac	quired, Di	sposed	of, or Be	neficial	y Owned				
Dat			Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Yea		Code (Ins	on Dispose	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)		5. Amour Securitie Beneficia Owned F Reported	s ally following	Form:	Direct of Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code V	Amoun	(A) or (D)	Price	Transact (Instr. 3 a	tion(s)			mad. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	Co	nsactior de (Instr			6. Date Exercisable a Expiration Date (Month/Day/Year)		7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Co	de V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$23.51	06/03/2014		А		12,000		(1)	06/02/2024	Common Stock	12,000	\$0	12,000	0	D	
Stock Option (Right to	\$23.51	06/03/2014		A		12,000		(2)	06/02/2024	Common Stock	12,000	\$0	12,00	0	D	

Explanation of Responses:

- 1. This option may be exercised and shall be vested as to 1/36th of the shares subject to this option when optionee completes each continuous month of service following the grant date.
- 2. This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date.

Brett A. Grimaud, Attorney-in-

Fact

** Signature of Reporting Person

06/05/2014

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.